In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats

Biology of the Neonate

Volumn 89, Issue 4, 2006, Pages 251-256

  Toyoshima, Katsuaki ^a,b   Momma, Kazuo ^a   Imamura, Shinichiro ^a   Nakanishi, Toshio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Amrinone; Ductus arteriosus; Milrinone; Phosphodiesterase 3 inhibitor

Indexed keywords

AMRINONE; INDOMETACIN; MILRINONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DUCTUS ARTERIOSUS; FETUS; FREEZING; MICROSCOPE; MICROTOME; NONHUMAN; POSTNATAL CARE; PREGNANCY; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANIMALS, NEWBORN; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; FEMALE; INDOMETHACIN; MILRINONE; PREGNANCY; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR;

EID: 33745108918     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089954     Document Type: Article

References (25)

1. Dasgupta SJ, Gill AB: Hypotension in the very low birthweight infant: the old, the new, and the uncertain. Arch Dis Child Fetal Neonatal Ed 2003;88:F450-F454.
2. Artman M, Mahony L, Teitel DF: Cardiovascular drug therapy; in Artman M, Mahony L, Teitel DF (eds): Neonatal Cardiology. New York, McGraw-Hill, 2002, pp 209-230.
3. Morgan JP, Gwathmey JK, DeFeo TT, Morgan KG: The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle. Circulation 1986;73:65-77.
4. Ooi H, Colucci WS: Pharmacological treatment of heart failure; in Hardman JG, Limbird LE, Gilman AG (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed 10. New York, McGraw-Hill, 2001, pp 901-932.
5. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-748.
6. Komas N, Movsesian M, Kedev S, Degerman E, Belfrage P, Manganiello VC: cGMP-inhibited phosphodiesterase (PDE3); in Schudt C, Dent G and Rabe KF (eds): Phosphodiesterase Inhibitors. London, Academic Press, 1996, pp 89-110.
7. LeJemtel TH, Gumbardo D, Chadwick B, Rutman HI, Sonnenblick EH: Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. Circulation 1986;73(suppl III):III213-III218.
8. Bristow MR, Port JD, Kelly RA: Treatment of heart failure: pharmacological methods; in Braunwald E, Zipes DP, Libby P (eds): Heart Disease, ed 6. Philadelphia, Saunders, 2001, pp 562-599.
9. Seino Y, Takano T, Hayakawa H, Kanmatsuse K: Hemodynamic effects and pharmacodynamics of oral milrinone for short-term support in acute heart failure. Cardiology 1995;86:34-40.
10. Bailey JM, Miller BE, Lu W, Tosone SR, Kanter KR, Tam VK: The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. Anesthesiology 1999;90:1012-1018.
11. Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL: Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 1995;23:1907-1914.
12. Ramamoorthy C, Anderson GD, Williams GD, Lynn AM: Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg 1998;86:283-289.
13. Teshima H, Tobita K, Yamamura H, Takeda A, Motomura H, Nakazawa M: Cardiovascular effects of a phosphodiesterase III inhibitor, amrinone, in infants: non-invasive echocardiographic evaluation. Pediatr Int 2002;44:259-263.
14. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL: Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107:996-1002.
15. Kato F, Kim S, Ogita H, Tsumura K, Kikuchi K: The effects of intravenous olprinone for the neonates with heart failure (in Japanese with English abstract). Acta Neonat Jpn 2003;39:25-30.
16. Kato F, Yokoyama A: Blood concentrations of olprinone HCl in neonates (abstract, in Japanese). Journal of Japan Society for Premature and Newborn Medicine 2004;16:396.
17. Yasuda K, Koyama N, Nomura T, Makino Y, Murata M, Takenaka M, Yamada T, Takeuchi M, Kouwaki M, Itou T, Hujita N, Shibata M, Suzuki Y: Effects of phosphodiesterase 3 inhibitors to premature PDA (abstract, in Japanese). Journal of Japan Society for Premature and Newborn Medicine 2004;16:395.
18. Nakamura M, Yamanouchi T, Taguchi T, Ogita K, Suita S: Effect of phosphodiesterase III inhibitor on persistent pulmonary hypertension of neonate associated with congenital diaphragmatic hernia: a case report (in Japanese with English abstract). J Jpn Soc Pediatr Surg 2001;37:1073-1077.
19. Momma K, Toyono M: The role of nitric oxide (NO) in dilating the fetal ductus arteriosus in rats. Pediatr Res 1999;46:311-315.
20. Momma K, Nishihara S, Ota Y: Constriction of the fetal ductus arteriosus by glucocorticoid hormones. Pediatr Res 1981;15:19-21.
21. Momma K, Konishi T, Hagiwara: Characteristic morphology of the constricted fetal ducts arteriosus following maternal administration of indomethacin. Pediatr Res 1985;19:493-500.
22. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods used in circulation research. Circ Res 1980;47:1-9.
23. Walsh RS, Mentzer RM Jr: Role of cyclic nucleotides in relaxation of fetal lamb ductus arteriosus. Surgery 1987;102:313-318.
24. Narumiya S, Sugimoto Y, Ushikubo F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
25. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-291.